811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Minerals Technologies preliminarily reported first-quarter 2025 sales of $492 million and operating income of $63 million, below its guidance of $500 million and $70 million. It also recorded a $215 million reserve for talc-related claims tied to its subsidiary BMI OldCo's Chapter 11 case, which could weigh on shareholders if the costs exceed the reserve or the case is not resolved as expected.
Q1 2025 preliminary sales of $492 million vs. prior guidance of $500 million; operating income of $63 million vs. guidance of $70 million
$215 million provision to establish a reserve for talc-related claims and BMI OldCo's Chapter 11 costs, including $30 million of added debtor-in-possession financing approved April 14, 2025
Cost savings program of about $10 million annualized with a $5.5 million severance and related charge; full run-rate savings expected by early 2026
Management said March sales improved to a run rate above initial Q1 guidance; more outlook details to come on the April 25, 2025 earnings call
Jazz Pharmaceuticals Ireland Limited agreed on April 7, 2025 to a preliminary class settlement with indirect Xyrem purchasers, paying $145 million in a lump sum from cash on hand. The company expects a pre-tax charge of about $145 million in the first quarter of 2025, and the deal remains subject to court approval. Shareholders face a known cash cost and a charge, and the company warns that further settlements with other plaintiffs may add significant charges.
Lump-sum payment of $145 million, funded with cash on hand
Expected pre-tax charge of approximately $145 million in the first quarter of 2025
Settlement requires Court approval and can be rescinded if a specified percentage of potential class members opt out
Company may enter additional settlements with remaining plaintiffs, which could be significant; the company denies wrongdoing
Pacira and its subsidiary settled all outstanding claims in patent litigation over EXPAREL with Fresenius Kabi, eVenus and Jiangsu Hengrui. Under the agreement, Pacira will license Fresenius Kabi to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. starting in early 2030, with unlimited generic sales permitted from 2039, both before the July 2, 2044 expiration of the last Orange Book-listed EXPAREL patent. Pacira will also pay the Fresenius Parties $7.0 million, which it said reflects expected savings from avoiding continued litigation costs.
Settlement entered April 7, 2025, covering seven listed patent infringement suits and related actions
Volume-limited generic entry starts in early 2030 at a confidential percentage that begins in the high single digits of U.S. volumes and rises to a maximum in the high thirties
Unlimited generic license begins no earlier than 2039, before the July 2, 2044 patent expiration
Pacira will pay the Fresenius Parties $7.0 million; the full agreement will be filed with the 10-Q for the quarter ending March 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.